Medical Tidbits, This Bobcat Has Nine Lives: A Surgically-Repaired Big Cat Returns to the Wild in Oregon

bobcat gets surgically repaired leg.

When a bobcat was discovered by a motorist in January by the side of the highway after being hit by a car, her prognosis was grim. She was dehydrated, skinny and suffering from a leg fracture that had left her femur shattered into pieces.

Last week, less than six months after her ordeal began, she was released back into the Oregon wilderness—and it was all thanks to some big-hearted veterinarians and a donation from DePuy Synthes.

Repairing a Natural Born Runner
The bobcat was taken to Oregon State University’s College of Veterinary Medicine, where she was examined by Dr. Jennifer Warnock, Associate Professor of Small Animal Surgery.

“This was no house cat,” recalls Dr. Warnock. “Bobcats have to run many square miles every day, and hunt for a living. She is the ultimate athlete in the most unforgivable environment, so that femur had to be 150%.”

After determining the bobcat was a candidate for surgery, Warnock and her team used a DePuy Synthes plate and screws for the complex surgery to repair the big cat’s leg. The medical devices were provided through a donation to Oregon State by the DePuy Synthes Vet team. read more

Merck Commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17

Investment reflects company’s commitment to innovation in fertility research  Globally, six projects receive funding from this grant cycle Darmstadt, Germany, July 6, 2016 – Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program by awarding grants totalling €1.5 million in 2016/17. The announcement was made at the 32nd annual meeting of European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Helsinki, Finland.

NeuroVive announces Arbutus Biopharma’s notice of termination

Lund, Sweden, July 6, 2016 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, Inc.) has given NeuroVive a purported notice of termination of the license agreement signed in 2014, related to the development and commercialization of NeuroVive’s compound NVP018 for oral treatment of HBV.  Arbutus’ notice, which NeuroVive questions on several grounds and in respect of which NeuroVive has reserved its rights, is a consequence of Arbutus’s decision to discontinue development of OCB-030 (NVP018), as communicated in October 2015. The fate of the license remains under discussion between the parties,

Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca to Heptares

TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified today by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca. read more

Acerus Completes NATESTO® U.S. Transition

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the completion of the NATESTO® U.S. transition from an affiliate of Endo International plc (NASDAQ:ENDP) (TSX:ENL) back to Acerus, and subsequently to Aytu BioScience, Inc. (OTCQX:AYTU). Aytu will now assume responsibility for the U.S. commercialization of NATESTO®, the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism.

Varithena Earns FDA Approval for 30 Day Post-Activation Shelf Life

Update provides physicians enhanced flexibility in aligning procedures to practice needs

WEST CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–BTG plc (LSE:BTG), the specialist healthcare company, announced that the U.S. Food and Drug Administration has approved an extension of the post-activation shelf life of Varithena (polidocanol injectable foam) 1% to thirty days from seven. read more

HiberGene Launches HG Group B Streptococcus Test

New test will diagnose the presence of Group B Streptococcus in pregnant women and neonates

DUBLIN–(BUSINESS WIRE)–Hibergene Diagnostics, a company focused on the application of molecular technology to infectious disease testing, has launched its HG Group B Streptococcus (GBS) Test.

The GBS test, which has been developed for use in clinical settings, can be used to rapidly and accurately diagnose the presence of Group B Streptococcus in pregnant women and neonates. The test takes under an hour, is highly accurate and can be tested near patient, without the need for expensive laboratory equipment.

Zambon Launches Xadago® (Safinamide) in the Netherlands for Patients with Mid- to Late-Stage Parkinson’s Disease

  • Zambon today announces the launch in the Netherlands of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’s disease (PD) medications, in mid- to late-stage PD
  • Safinamide is a new chemical entity with a unique dopaminergic and non-dopaminergic mode of action

MILAN–(BUSINESS WIRE)–Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced the launch of Xadago® (safinamide) in the Netherlands for the treatment of mid- to late-stage Parkinson’s disease (PD). read more

Luminex Corporation Receives FDA Clearance and CE-IVD Mark for the ARIES M1 System

PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced it has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the ARIES® M1 System. Designed for lower throughput clinical labs, the ARIES® M1 System is a fully integrated, sample to answer platform for performing real-time PCR assays.

The ARIES M1 System is designed to empower satellite clinical laboratories to take advantage of the same benefits as Luminex’s higher throughput ARIES System, with features such as an intuitive system interface, STAT or batch testing, and true walkaway capability. The system extracts, amplifies and detects nucleic acid targets from a variety of sample types. Once the cassettes are loaded onto the instrument, results are generated without additional technical intervention. The system can process up to six different samples, and one to six assays, at a time.

Arizona patient will receive first U.S.-approved fully dissolving heart stent

PRNewswire-USNewswire/ — A heart stent that dissolves completely over time and that represents the next major advance in coronary artery disease treatment will be implanted July 6 in the first U.S. patient at HonorHealth Scottsdale Shea Medical Center. The revolutionary device received approval from the U.S. Federal Drug Administration on July 5 after years of clinical research and trials.

Manufactured by Abbott Vascular, the stent is a small polymer tube that opens clogged arteries and helps restore blood flow to the heart. The stent dissolves completely in the body two to three years after implantation.

“This is a game changer in coronary disease management,” said David G. Rizik, MD, an HonorHealth interventional cardiologist who was a principal investigator for the device during clinical trials at HonorHealth Research Institute. Rizik will perform the first FDA-approved implant in the United States. “It’s the next big advance.”



Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.